Showing results (351-360 of 528) with videos related to

Sort By:
Pageof 53
Frontiers in Immunology|April 25, 2022
Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human GlioblastomaParis M Kollis, Lisa M Ebert, John Toubia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|December 22, 1999
Analysis of intrapulmonary O(2) concentration by MR imaging of inhaled hyperpolarized helium-3B Eberle, N Weiler, K Markstaller, et al.
Oncotarget|March 20, 2015
A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer propertiesMelissa R Pitman, Jason A Powell, Carl Coolen, et al.
Journal for Immunotherapy of Cancer|May 16, 2024
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancersTessa Gargett, Nga T H Truong, Bryan Gardam, et al.
International Journal of Molecular Sciences|April 30, 2021
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in GlioblastomaSakthi Lenin, Elise Ponthier, Kaitlin G Scheer, et al.
The Journal of Biological Chemistry|January 19, 2020
Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβScott M Ebert, Steven A Bullard, Nathan Basisty, et al.
Frontiers in Immunology|June 30, 2023
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapyChad Pickering, Paul Aiyetan, Gege Xu, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
Pageof 53